Physician profile
Mark M Kreit
NPI 1083771976
$498.18
in general payments reported to CMS, 2019-2025
13 companies · $89.01 in 2025
The $89.01 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $170 · 2020: $71.75 · 2021: $127 · 2022: $21.70 · 2024: $18.17 · 2025: $89.01.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $107.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $134.01 | 2021-2025 | Veozah |
| Sunovion Pharmaceuticals INC. | $66.07 | 2019 | |
| Paratek Pharmaceuticals, INC. | $60.26 | 2020-2021 | |
| Sumitomo Pharma America, INC. | $40.00 | 2025 | Gemtesa |
| Allergan, INC. | $36.22 | 2019 | |
| Pfizer INC. | $31.95 | 2019 | |
| Glaxosmithkline, LLC. | $26.50 | 2020 | |
| Merck Sharp & Dohme LLC | $21.70 | 2022 | |
| Galderma Laboratories, L.P. | $20.19 | 2019 | |
| Xeris Pharmaceuticals, INC. | $18.17 | 2024 | Keveyis |
| Alkermes, INC. | $16.24 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $15.74 | 2019 | |
| Genentech USA, INC. | $11.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Kreit listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.